Skip to content

Genetic Research of Monogenic Obesity in a Pediatric Cohort With Severe and Early Onset Obesity

Genetic Research of Monogenic Obesity in a Pediatric Cohort With Severe and Early Onset Obesity

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05362565
Acronym
OBEGENE
Enrollment
100
Registered
2022-05-05
Start date
2022-10-01
Completion date
2024-01-01
Last updated
2022-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Monogenic Obesity

Keywords

monogenic obesity, pediatric, early onset obesity, genetic disease

Brief summary

Obesity is a frequent disease mainly caused by environmental/polygenic factors and more rarely caused by the alteration of a single gene (monogenic obesity). The diagnosis of these rare forms can lead to personalized management (new treatments, prognosis, adapted hygienic and dietary rules) and family screening. The use of a panel covering the known causes of monogenic obesity on a pediatric cohort of severe and early obesity will allow to evaluate the relevance of these analyses to adapt the management of this type of patients.

Interventions

The DNA study will be carried out from saliva sample 1 saliva sample per patient will be performed at the inclusion visit

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Recruitment age: 2-17 years * Body mass index, greater than the International Obesity Task Force (IOTF) 30 curve before the age of 5 * Care at the specialized pediatric obesity center (CSO) of the Bordeaux University Hospital * Informed consent signed

Exclusion criteria

* no informed consent

Design outcomes

Primary

MeasureTime frame
Positivity rate of patients for whom a diagnosis of monogenic obesity will be obtained when all analyses have been performed.Inclusion visit

Secondary

MeasureTime frame
Number of Patients eligible for a drug targeting single-gene obesityInclusion visit
Number of patients for whom a genetic finding will have changed management and description of changes.Inclusion visit

Countries

France

Contacts

Primary ContactLouis LEBRETON
louis.lebreton@chu-bordeaux.fr05 57 82 21 78
Backup ContactWafae BELCADI
wafae.belcadi@chu-bordeaux.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026